<DOC>
	<DOC>NCT01289132</DOC>
	<brief_summary>The purpose of this study was to evaluate the dose-response relationships of azilsartan, once daily (QD) in participants with mild to moderate uncomplicated essential hypertension.</brief_summary>
	<brief_title>Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension</brief_title>
	<detailed_description>Hypertension is known to cause multiple organ damage by being combined with not only blood pressure but also other hemodynamics, endocrinological/metabolic abnormalities and genetic factors. This becomes a medically and medical-economically significant problem in Japan The significance of early treatment of hypertension and of long-term control of blood pressure has been increasing year by year. Takeda Pharmaceutical Company Limited invented TAK-536 (azilsartan), an angiotensin II receptor blocker for decreasing blood pressure. This study investigating the efficacy and safety of azilsartan using candesartan cilexetil, a widely used antihypertensive drug, as a reference control.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Has mild to moderate uncomplicated essential hypertension. Has a sitting diastolic blood pressure between 95 and &lt;110 mmHg and sitting systolic blood pressure between 150 and &lt;180 mmHg at placebo runin period (Week 2) or randomization visit. Has a cardiovascular disease or symptoms Has been treated with more than 3 different antihypertensives within 27 days prior to placebo runin period. Has a significant hepatic disorder, hyperkalemia, malignant tumor or significant renal impairment.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>